The proceeds will be used to advance iDEL Therapeutics' two proprietary lead programs towards clinical evaluation. Leveraging different modalities with the potential to address a range of solid tumors, the pipeline candidates are based on the company's proprietary shuttling technology. This pan-cancer platform enables evasion of endosomal entrapment and prevents subsequent degradation of the transported compound, a factor that can impair drug delivery and treatment efficacy, particularly for large molecules such as antibodies and their derivatives.
"iDEL Therapeutics' concept to unlock new cancer treatments represents an exciting new opportunity with the potential to significantly impact the oncology landscape," said Marcus Kostka, PhD, Co-Founder and CEO of iDEL Therapeutics. "Our technology's broad applicability to a range of drug classes harbors the potential to improve treatment outcomes for patients living with a range of high-need cancer indications. Together with the leadership team, I look forward to expanding our preclinical proof-of-concept data, advancing our lead candidates toward the clinic and exploring additional possibilities for improved cancer treatments."
Concurrent with the financing, iDEL Therapeutics announced its leadership team which combines decades of expertise in biopharma, drug development and company building.
"Despite continuous advancements and a deeper understanding of cancer in our industry, ...
